pla1a Antibody

What is PLA1A and what cellular functions does it perform?

PLA1A (Phospholipase A1 member A) is a phospholipase that hydrolyzes fatty acids at the sn-1 position of phosphatidylserine and 1-acyl-2-lysophosphatidylserine. This secreted protein plays several important biological roles including:

• Hydrolyzing phosphatidylserine (PS) in liposomes and apoptotic cells

• Activating platelets where resulting 2-acyl-lysophosphatidylserine acts as a lipid mediator for mast cells, T cells, and neural cells

• Participating in the antiviral innate immune response through modulation of TANK-binding kinase 1 (TBK1) activation

The primary function appears to be production of lysophospholipid mediators, with additional identified roles in viral processes and immune signaling.

What applications are PLA1A antibodies validated for in research?

PLA1A antibodies have been validated for several key research applications:

These applications enable researchers to detect and quantify PLA1A in various experimental contexts, with validation primarily performed in human tissue samples, particularly kidney tissue .

How does PLA1A contribute to antiviral immune responses?

PLA1A plays a significant role in antiviral innate immune responses through several mechanisms:

• Required for RNA virus-induced type I interferon (IFN) production

• Functions at the TBK1 level of the signaling pathway

• Controls phosphorylation and kinase activity of TBK1

• Essential for TBK1-MAVS (mitochondrial antiviral signaling protein) interactions

• Influences mitochondrial morphology and recruitment of TBK1-associated complexes to mitochondria

• Knockdown of PLA1A significantly impairs antiviral responses to Sendai virus (SeV)

These functions collectively position PLA1A as an important mediator in the cellular defense against viral infections.

How can I optimize detection of PLA1A in different cellular compartments?

Optimizing PLA1A detection requires consideration of cellular localization and fractionation methods:

For comprehensive subcellular detection, implement:

• Nuclear and cytoplasmic extraction using verified extraction kits (e.g., Beyotime Biotechnology #P0027)

• Mitochondrial isolation techniques (e.g., cell mitochondria isolation kit, Beyotime Biotechnology #C3601)

• For immunofluorescence applications in tissue sections, begin optimization at 20 μg/mL and adjust based on signal-to-noise ratio

• When performing Western blot analysis, compare results between whole cell lysates and subcellular fractions to ensure complete detection

Additionally, consider that PLA1A has been observed to associate with mitochondria in some experimental contexts, which may require specialized extraction protocols to maintain protein-organelle associations.

What experimental approaches can resolve discrepancies between observed (68 kDa) and calculated (49.7 kDa) molecular weights of PLA1A?

The discrepancy between observed (68 kDa) and calculated (49.7 kDa) molecular weights of PLA1A likely derives from post-translational modifications. To investigate this phenomenon:

• Perform deglycosylation assays using enzymes such as PNGase F to remove N-linked glycans

• Utilize phosphatase treatments to assess contribution of phosphorylation to apparent molecular weight

• Compare migration patterns of recombinant PLA1A (lacking post-translational modifications) with endogenous protein

• Employ mass spectrometry to characterize specific modifications

• Use isoform-specific detection methods, as at least three isoforms of PLA1A are known to exist

These approaches can help elucidate whether the observed weight difference is due to glycosylation, phosphorylation, or other modifications that affect protein mobility in SDS-PAGE.

How does PLA1A's interaction with viral proteins inform its role in cellular immunity?

PLA1A exhibits significant interactions with viral proteins that provide insight into its immunological functions:

• PLA1A interacts with HCV E2, NS2, and NS5A proteins, facilitating NS2-E2 and NS2-NS5A complex formation essential for viral assembly

• Despite facilitating HCV assembly, PLA1A also participates in antiviral responses by modulating TBK1 activation

• This dual functionality suggests PLA1A may represent a convergence point between viral manipulation and host defense mechanisms

To experimentally investigate these interactions:

• Perform co-immunoprecipitation assays with tagged viral and PLA1A proteins

• Use confocal microscopy to visualize co-localization during infection

• Employ proximity ligation assays to confirm direct protein interactions in situ

• Develop domain mapping experiments to identify critical interaction regions

• Compare PLA1A's behavior across multiple virus families to determine specificity versus generality of these interactions

What are the optimal conditions for preserving PLA1A antibody activity during experimental procedures?

To maintain optimal PLA1A antibody activity throughout experimental procedures:

Additionally, when performing kinase activity assays involving PLA1A and TBK1, maintain specific buffer conditions (20 mM tris-HCl, 1 mM EGTA, 5 mM MgCl2, 0.02% 2-mercaptoethanol, 0.03% Brij-35, BSA [0.2 mg/mL], 20 mM ATP) and conduct reactions at 30°C for optimal enzymatic activity .

What controls should be included when using RNA interference to study PLA1A function?

When employing RNA interference to investigate PLA1A function, include these essential controls:

• Validation controls:

  • Confirm knockdown efficiency at both mRNA level (qRT-PCR) and protein level (Western blot)

  • Use at least two independent siRNA sequences targeting PLA1A to rule out off-target effects

  • Include siRNA targeting sequence: 5′-GGATAGGACTGGTGGAACA-3′ which has been validated in previous studies

• Experimental controls:

  • Non-targeting siRNA with similar GC content to the PLA1A siRNA

  • Mock transfection (transfection reagent only)

  • Untransfected cells

  • Rescue experiments with siRNA-resistant PLA1A expression constructs

• Functional readouts:

  • Measure type I IFN production (IFNB1, ISG15, ISG56) following viral stimulation

  • Assess TBK1 phosphorylation and kinase activity

  • Evaluate mitochondrial morphology and TBK1-MAVS interactions

Optimal transfection conditions include using Lipofectamine RNAiMAX with forward transfection method on cells at 60-80% confluence, with experimental assays conducted 48 hours post-transfection.

How can I establish specificity of PLA1A antibody signal in my experimental system?

Establishing antibody specificity requires multiple validation approaches:

• Positive and negative tissue/cell controls:

  • Use tissues/cells known to express PLA1A (e.g., human kidney tissue) as positive controls

  • Include tissues with low/no PLA1A expression as negative controls

  • Apply PLA1A overexpression systems as additional positive controls

• Molecular validation:

  • Perform pre-adsorption experiments using the immunogenic peptide

  • Compare staining patterns using antibodies targeting different epitopes of PLA1A

  • Implement PLA1A knockdown controls (siRNA) to demonstrate signal reduction

• Cross-reactivity assessment:

  • Test antibody against recombinant isoforms of PLA1A

  • Confirm the antibody detects all three known isoforms if studying total PLA1A

  • Verify species reactivity (documented for human and rat PLA1A)

• Technical controls:

  • Include secondary antibody-only controls

  • Implement concentration gradients to determine optimal antibody dilution

  • For immunofluorescence, use counterstains to confirm subcellular localization

How should I interpret changes in PLA1A expression during viral infection?

Interpreting PLA1A expression changes during viral infection requires multifaceted analysis:

• Temporal considerations:

  • PLA1A expression is upregulated by dsRNA transfection and during late stages of HCV infection

  • Establish a complete expression timeline from initial infection through viral replication/assembly

  • Different viruses may induce PLA1A at different timepoints reflecting distinct viral strategies

• Functional correlation:

  • Compare PLA1A expression levels with:

    • Viral replication markers

    • Interferon response measurements (e.g., IFNB1, ISG15, ISG56 expression)

    • TBK1 phosphorylation status

    • Mitochondrial morphological changes

• Cell-type specificity:

  • PLA1A expression in THP-1-derived macrophages is upregulated by lipopolysaccharide (TLR4 ligand)

  • This upregulation is inhibited by corticosteroids

  • Analyze whether expression patterns differ between immune and non-immune cell types

Understanding these patterns enables differentiation between PLA1A induction as part of the antiviral response versus potential viral subversion of PLA1A functions.

What approaches can resolve discrepancies in PLA1A functional studies between different cell types?

When encountering discrepancies in PLA1A functional studies across cell types:

• Baseline expression analysis:

  • Quantify endogenous PLA1A expression levels across studied cell types

  • Determine relative expression of all three PLA1A isoforms in each cell type

  • Profile expression of PLA1A-interacting partners (e.g., TBK1, MAVS) to identify potential stoichiometric variations

• Signaling pathway context:

  • Map TBK1 pathway component expression across cell types

  • Assess basal activation states of innate immune signaling components

  • Evaluate cell-type specific responses to standard immune stimuli

• Experimental harmonization:

  • Standardize protein/RNA extraction protocols across cell types

  • Implement identical knockdown efficiencies when comparing functional outcomes

  • Use multiple detection methods (qPCR, Western blot, immunofluorescence) to verify findings

• Functional readout calibration:

  • Develop reporter systems calibrated to cell-type specific baseline responses

  • Employ multiple functional readouts (e.g., protein interactions, enzymatic activity, downstream gene expression)

  • Consider kinetics of responses, as timing may vary between cell types

How does PLA1A's enzymatic activity correlate with its role in immune signaling?

Understanding the relationship between PLA1A's enzymatic function and immune signaling role:

• Structure-function analysis:

  • Compare wild-type PLA1A with catalytically inactive mutants in immune signaling assays

  • Investigate whether phospholipase activity is required for TBK1 interaction and activation

  • Determine if enzymatic products (lysophospholipids) directly affect immune signaling pathways

• Lipid-mediated effects:

  • Assess whether 2-acyl-lysophosphatidylserine (the product of PLA1A activity on phosphatidylserine) influences:

    • Mitochondrial membrane composition and MAVS localization

    • TBK1 recruitment to signaling complexes

    • IRF3 phosphorylation and nuclear translocation

• Protein interaction domains:

  • Identify which domains of PLA1A are required for:

    • Enzymatic activity

    • TBK1 binding

    • MAVS interactions

    • Viral protein interactions (e.g., HCV NS2, E2, NS5A)

• Signaling kinetics correlation:

  • Compare enzymatic activity timecourse with signaling activation timecourse

  • Determine whether phospholipase inhibitors block immune signaling functions

  • Investigate whether lipid environment alterations affect PLA1A-dependent immune responses

This experimental framework helps distinguish between PLA1A's enzymatic and potential scaffolding roles in immune signaling.

What are emerging applications of PLA1A antibodies in studying organelle dynamics during immune responses?

PLA1A antibodies show promising applications in organelle dynamics research:

• Mitochondrial morphology analysis:

  • PLA1A knockdown studies have revealed altered mitochondrial morphology during viral responses

  • Super-resolution microscopy with PLA1A antibodies can track real-time changes in mitochondrial networks

  • Multi-color imaging with organelle markers can reveal PLA1A trafficking between compartments

• Membrane contact site investigation:

  • PLA1A's role in modifying phospholipids may influence membrane contact sites between organelles

  • Proximity ligation assays using PLA1A antibodies can identify novel interacting proteins at these junctions

  • Combined immunoprecipitation and lipidomics approaches can identify local lipid environment changes

• Immune synapse dynamics:

  • Given PLA1A's role in immune signaling, antibodies can be used to track its recruitment to immune synapses

  • Live-cell imaging with fluorescently tagged antibody fragments could reveal dynamic behaviors

  • Correlative light-electron microscopy could provide ultrastructural context to PLA1A localization

These approaches expand PLA1A research beyond traditional protein detection toward understanding spatial and temporal dynamics in immune responses.

How might PLA1A research inform therapeutic approaches to viral infections?

PLA1A research offers several potential therapeutic avenues:

• Dual-targeting strategies:

  • PLA1A appears to play roles in both viral assembly (for HCV) and antiviral responses

  • Understanding this dual functionality could inform development of:

    • Small molecule modulators that enhance antiviral functions while inhibiting proviral activities

    • Targeted approaches that disrupt virus-specific interactions without compromising immune signaling

• Pathway-specific interventions:

  • PLA1A's position in the TBK1-dependent signaling pathway represents a potential intervention point

  • Therapeutic modulation might enhance broader innate immune responses without directly targeting viral components

  • This could provide advantages against viruses that rapidly develop resistance to direct-acting antivirals

• Biomarker development:

  • Changes in PLA1A expression or activation state during infection could serve as biomarkers for:

    • Disease progression

    • Treatment response

    • Immune activation status

  • Antibody-based diagnostics could facilitate monitoring these parameters in clinical settings

Expanding our understanding of PLA1A biology continues to reveal new opportunities for therapeutic intervention in viral infections.